In different subtypes of breast cancer, the triple negative subtype, defined as no/few expression of ER, PR and Her2 and usually harboring TP53 and BRCA1 mutation, comprises 10–20% of all breast cancers, and are at high risk of tumor recurrence due to the lack of reliable specific target of chemotherapy [18]. This evidence concerns the gene ERBB2 and breast cancer.